Board of Trustees
Cancer52 benefits hugely from the expertise and skills within the trustees of the board who give their time to help drive forward the agenda for rare and less common cancers. All are strong, senior and experienced individuals at board and strategy level, established and credible in their own right.
The board of trustees was initially established in early 2012 alongside the creation of the organisation’s status as a not for profit company limited by guarantee. Board membership has been updated since and continues to represent a vibrant and experienced group of people committed to the aims of Cancer52.
Baroness Morgan of Drefelin (Previously Chief Executive of Breast Cancer Now) sits at the helm of the
organisation as honorary president, giving Cancer52 both a route through to the seat of government, as well as guidance on the lessons to be learnt from the bigger cancer organisations.
The board is responsible for shaping the direction of Cancer52 and is lead by its Chair, Anne MacDowell.
Honorary President Cancer52
Baroness
Delyth Morgan
Chair, Cancer52
Anne MacDowell
CEO, Cancer52
Chris
Walden
CEO, AMMF - The Cholangiocarcinoma Charity
Helen Morement
Chair, GIST CANCER UK
Nic Puntis
Doctor
Dr Max Brodermann
Head of HR, Organisational Development and Volunteering, Blood Cancer UK
Retired Financial Consultant
Clare Clifton
Michael Draeger
Research Assistant
Sophie Davies
Head of Policy & Public Affairs, Anthony Nolan
Yasmin Sheikh
Civil Servant
Anna Evans
Communications Director
Amanda Boughey
